Integra Lifesciences Holdings Corp (NASDAQ:IART) CEO Sells $15,137,500.00 in Stock

Integra Lifesciences Holdings Corp (NASDAQ:IART) CEO Peter J. Arduini sold 250,000 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $60.55, for a total transaction of $15,137,500.00. Following the completion of the sale, the chief executive officer now owns 433,017 shares of the company’s stock, valued at approximately $26,219,179.35. The transaction was disclosed in a document filed with the SEC, which is available at this link.

IART traded up $2.05 during trading on Tuesday, reaching $63.10. 47,307 shares of the company’s stock were exchanged, compared to its average volume of 455,090. The company’s fifty day moving average price is $61.13 and its 200-day moving average price is $55.01. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.82 and a current ratio of 2.76. Integra Lifesciences Holdings Corp has a fifty-two week low of $42.14 and a fifty-two week high of $66.41. The firm has a market capitalization of $5.17 billion, a PE ratio of 26.10, a P/E/G ratio of 1.90 and a beta of 1.10.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.08. Integra Lifesciences had a return on equity of 16.30% and a net margin of 6.76%. The company had revenue of $383.60 million for the quarter, compared to the consensus estimate of $373.29 million. During the same quarter in the prior year, the business posted $0.60 EPS. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. Research analysts forecast that Integra Lifesciences Holdings Corp will post 2.73 earnings per share for the current fiscal year.

IART has been the topic of a number of research reports. Zacks Investment Research upgraded shares of Integra Lifesciences from a “hold” rating to a “buy” rating and set a $65.00 target price on the stock in a research report on Monday, September 2nd. JMP Securities boosted their price objective on shares of Integra Lifesciences to $75.00 in a research report on Thursday, July 25th. BidaskClub downgraded Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 28th. Royal Bank of Canada set a $66.00 price objective on Integra Lifesciences and gave the company a “hold” rating in a research report on Friday, July 26th. Finally, Oppenheimer lifted their target price on Integra Lifesciences from $65.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $62.67.

A number of large investors have recently added to or reduced their stakes in IART. Clearbridge Investments LLC grew its position in shares of Integra Lifesciences by 21.2% during the 1st quarter. Clearbridge Investments LLC now owns 2,442,164 shares of the life sciences company’s stock worth $136,077,000 after buying an additional 426,578 shares during the period. Janus Henderson Group PLC grew its holdings in Integra Lifesciences by 13.1% during the second quarter. Janus Henderson Group PLC now owns 3,248,870 shares of the life sciences company’s stock valued at $181,449,000 after purchasing an additional 375,546 shares during the period. Point72 Asset Management L.P. grew its holdings in Integra Lifesciences by 198.1% during the second quarter. Point72 Asset Management L.P. now owns 399,294 shares of the life sciences company’s stock valued at $22,301,000 after purchasing an additional 265,335 shares during the period. Fort Washington Investment Advisors Inc. OH bought a new stake in Integra Lifesciences in the first quarter valued at approximately $14,145,000. Finally, Vaughan Nelson Investment Management L.P. increased its stake in Integra Lifesciences by 26.1% in the first quarter. Vaughan Nelson Investment Management L.P. now owns 1,110,177 shares of the life sciences company’s stock valued at $61,860,000 after purchasing an additional 230,010 shares in the last quarter. 81.91% of the stock is currently owned by hedge funds and other institutional investors.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Recommended Story: What is an investor looking for in an SEC filing?

Insider Buying and Selling by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.